The issue of a national pharmacare program is more nuanced than it may appear at first glance, said Joe Farago during a presentation at the 2018 Halifax Benefits Summit on Sept. 20. “Canadians are starting to change their views,” said Innovative Medicines Canada’s executive director, private payers and investment, during the conference. Farago pointed to a national poll of health-care providers, managers and the […]
Plan sponsors and administrators walk a razor’s edge, striving to ensure members have access to the services they need while also making certain the plan is financially sustainable. Working collaboratively with health-care providers is a critical step, but these partnerships have often proved elusive, delegates heard at the 2018 Halifax Benefits Summit. “There is a disconnect. We […]
Public drug plan spending continued its upward trend in 2016-17, though at a much slower rate rather in 2015-16, according to a new report by the Patented Medicine Prices Review Board. The analysis, which focuses on the public drug plans participating in the National Prescription Drug Utilization Information System initiative, found spending increased just 1.9 per cent in 2016-17, […]
Universal pharmacare is an idea that has been kicking around for decades in Canada. Yet despite numerous studies calling for a universal single-payer pharmacare program to ensure all Canadians have access to prescription drugs, the country’s drug system remains a patchwork of public and private plans. This spring, the House of Commons’ standing committee on […]
While the move to more defined contribution-style health benefits plans provides greater clarity and flexibility to plan sponsors, it would be natural to wonder whether or not the available options are limited to the two extremes alone. The continuum of benefits plan design includes fully insured plans, fully self-insured (administration services-only or ASO) plans and hybrid […]
The federal government’s plan to increasingly regulate pharmaceutical costs could mean Canadians with rare diseases may lose access to new innovative drug treatments, according to a new study by the Fraser Institute. In 2019, the Patented Medicine Prices Review Board is planning to use new rules for establishing drug prices with the goal of lowering costs. “Drugs for […]
As September approaches, activity in the catastrophic stop-loss insurance market will start to heat up for self-insured plan sponsors. This is when the annual dance of plans obtaining their proposed premium for the coming year, and trying to find ways to mitigate the increase, hits a fever pitch. Imagine a province, without a single provincial insurer, […]
High-cost drugs accounted for 41.6 per cent of patented medicine sales in 2017, up from 8.3 per cent a decade earlier, according to the Patented Medicine Prices Review Board’s latest annual report. Federal Health Minister Ginette Petitpas Taylor tabled the report, which also illustrated a rise in the sales of patented medicines in 2017. Sales […]
The vast majority (87 per cent) of physicians said the knowledge that a patient has private drug coverage affects their prescribing behaviour, according to a survey by Merck Canada Inc. More specifically, the survey found 26 per cent of general practitioners and 28 per cent of specialists believe this knowledge widens the treatment options available to the patient. Other effects […]
How do the following sound as headlines for the cover of Benefits Canada? Are they likely to make the cut any time soon? • “My boss is 89” • “Remember when we went to the doctor’s office?” • “On-the-job diagnosis” • “Machines don’t need benefits” • “Artificial benefits” • “Shareholders elect first AI CEO (actuary’s […]